How soon after hip repair can a patient resume Eliquis (apixaban)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Resuming Eliquis After Hip Repair

For hip repair surgery (high bleeding risk), resume Eliquis 48-72 hours (2-3 days) postoperatively once adequate surgical hemostasis is established. 1

Timing Based on Bleeding Risk

Hip repair surgery is classified as high bleeding risk due to the extensive surgical dissection, bone work, and potential for significant postoperative bleeding. The evidence consistently supports delayed resumption:

High Bleeding Risk Surgery (Hip Repair)

  • Resume at 48-72 hours postoperatively 1, 2
  • Standard dose: Apixaban 5 mg twice daily
  • For patients at high thromboembolic risk, consider starting with a reduced dose (2.5 mg twice daily) for the first 2-3 days, then increase to full dose 1

Low Bleeding Risk Surgery (for comparison)

  • Resume at 24 hours postoperatively 1
  • This does NOT apply to hip repair

Practical Implementation Algorithm

Step 1: Assess Hemostasis

  • Verify surgical site hemostasis is adequate
  • No active bleeding from surgical drains
  • Stable hemoglobin without ongoing transfusion requirements

Step 2: Timing

  • Wait minimum 48 hours after surgery
  • Optimal window: 48-72 hours 2
  • The FDA label states "restart as soon as adequate hemostasis has been established" 3, but guidelines specify this means 48-72 hours for high-risk procedures

Step 3: Dosing Strategy

  • Standard approach: Resume full dose (5 mg twice daily) at 48-72 hours 1
  • High thromboembolic risk patients (mechanical valve, recent stroke, CHADS₂ ≥3): Consider apixaban 2.5 mg twice daily for first 2-3 days, then increase to 5 mg twice daily 1

Step 4: Bridging Considerations

  • No heparin bridging needed in most cases 2
  • If VTE prophylaxis needed during the 48-72 hour window: Use prophylactic-dose LMWH or UFH starting at least 6 hours post-surgery 2
  • Stop prophylactic anticoagulation 12 hours before starting therapeutic-dose Eliquis 2

Critical Precautions

Epidural Catheter Management

  • Do NOT start therapeutic-dose Eliquis with an epidural catheter in place 2
  • If epidural present: Use heparin for anticoagulation until catheter safely removed
  • Follow neuraxial anesthesia guidelines for catheter removal timing

Renal Function Monitoring

  • Check creatinine postoperatively before resuming Eliquis 2
  • Hip surgery and perioperative factors can affect renal function
  • Adjust dose if creatinine clearance changes significantly

Dose Adjustments

The standard 5 mg twice daily dose should be reduced to 2.5 mg twice daily if patient has ≥2 of the following 3:

  • Age ≥80 years
  • Weight ≤60 kg
  • Serum creatinine ≥1.5 mg/dL

Evidence Quality

The recommendations are based on:

  • 2017 French GIHP guidelines 2 - most recent comprehensive guideline
  • 2012 Blood journal expert consensus 1 - foundational perioperative DOAC management
  • FDA label 3 - regulatory guidance supporting 48-hour minimum for moderate-high risk procedures
  • 2014 Canadian guidelines 4 - supporting 48-72 hour window for high-risk procedures

The 48-72 hour window represents a balance between bleeding risk and thrombotic risk. Starting too early (within 24 hours) significantly increases bleeding complications 1, while the rapid onset of Eliquis (peak effect 1-3 hours) means delayed initiation beyond 72 hours may unnecessarily increase VTE risk 1.

Common Pitfall

Do not resume at 24 hours - this timing is only appropriate for low bleeding risk procedures (minor dental, skin procedures), NOT orthopedic surgery 1. Hip repair requires the longer 48-72 hour window due to high bleeding risk.

References

Related Questions

What is an appropriate replacement for Eliquis (apixaban) in a hospice patient?
After hip fracture repair, should I restart apixaban (Eliquis) or initiate enoxaparin (Lovenox) for venous thromboembolism prophylaxis?
What is the recommended duration of therapy with Eliquis (apixaban) for indications such as non‑valvular atrial fibrillation, acute deep‑vein thrombosis or pulmonary embolism, and postoperative thromboprophylaxis after hip or knee replacement?
What is the recommended anticoagulation regimen after hip fracture surgery?
Should the apixaban (Eliquis) dose be adjusted in a patient taking prednisone?
In a 50-year-old man with recurrent chest tightness radiating to the shoulder, a family history of premature sudden death, and a resting electrocardiogram showing left bundle branch block, what is the most appropriate test to assess the coronary arteries?
In a 58-year-old patient presenting with progressive dyspnea and paroxysmal nocturnal dyspnea, whose echocardiogram shows anterior wall hypokinesia and a left ventricular ejection fraction of 30%, what is the next best investigation?
Is iron supplementation indicated for benign prostatic hyperplasia (BPH)?
What is the recommended dosing regimen for cintapride, including initial dose, titration, and adjustments for older adults or patients with reduced renal function?
In rheumatoid arthritis, which of the following statements are correct: a) distal interphalangeal joints are affected, b) joint involvement is usually symmetrical, c) anti‑citrullinated protein antibodies (anti‑CCP) are specific for diagnosis, d) biological agents are first‑line therapy, e) patients have the same cardiovascular risk as the general population?
What is the appropriate management for vulvar pruritus?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.